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A Targeted LC-MS Strategy for Low-Abundant HLA
Class-I-Presented Peptide Detection Identiﬁes Novel
Human Papillomavirus T-Cell Epitopes
Renata Blatnik, Nitya Mohan, Maria Bonsack, Lasse G. Falkenby, Stephanie Hoppe,
Kathrin Josef, Alina Steinbach, Sara Becker, Wiebke M. Nadler, Marijana Rucevic,
Martin R. Larsen, Mogjiborahman Salek, and Angelika B. Riemer*
For rational design of therapeutic vaccines, detailed knowledge about target
epitopes that are endogenously processed and truly presented on infected or
transformed cells is essential. Many potential target epitopes (viral or
mutation-derived), are presented at low abundance. Therefore, direct
detection of these peptides remains a challenge. This study presents a method
for the isolation and LC-MS3-based targeted detection of low-abundant
human leukocyte antigen (HLA) class-I-presented peptides from transformed
cells. Human papillomavirus (HPV) was used as a model system, as the HPV
oncoproteins E6 and E7 are attractive therapeutic vaccination targets and
expressed in all transformed cells, but present at low abundance due to viral
immune evasion mechanisms. The presented approach included preselection
of target antigen-derived peptides by in silico predictions and in vitro binding
assays. The peptide puriﬁcation process was tailored to minimize
contaminants after immunoprecipitation of HLA-peptide complexes, while
keeping high isolation yields of low-abundant target peptides. The subsequent
targeted LC-MS3 detection allowed for increased sensitivity, which resulted in
successful detection of the known HLA-A2-restricted epitope E711–19 and ten
additional E7-derived peptides on the surface of HPV16-transformed cells.
T-cell reactivity was shown for all the 11 detected peptides in ELISpot assays,
which shows that detection by our approach has high predictive value for
immunogenicity. The presented strategy is suitable for validating even
low-abundant candidate epitopes to be true immunotherapy targets.
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1. Introduction
Immunotherapies targeting tumor-
speciﬁc antigens represent attractive
cancer treatments, as they allow focusing
the immune attack speciﬁcally on cancer
cells. Truly tumor-speciﬁc antigens can
either derive from oncogenic viruses
or from tumor-speciﬁc mutations (so-
called neoantigens). To be visible to
the immune system, peptide epitopes
derived from these antigens must be
presented on the cell surface on human
leukocyte antigen (HLA) molecules for
T-cell recognition.[1]
Cytotoxic CD8+ T-cells recognize
epitopes presented on HLA class-I
(HLA-I). HLA-I is a heterodimeric
membrane glycoprotein composed of an
α-chain and the non-covalently bound
β2-microglobulin (β2M). The HLA-I
complex typically binds short 8–11-
mer peptides. Epitopes are generated
from the whole cell proteome by the
cellular antigen processing machinery,
resulting in diverse epitope sequences
of various abundances presented at
the cell surface.[2] HLA-I molecules
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Signiﬁcance Statement
This study describes thedirect LC-MS3 detectionof 11out of
17preselectedHLA-A2-restrictedHPV16E6 andE7peptides
on the surface ofHPV-transformed cells, and shows immuno-
genicity of all of these. Interestingly, half of the detected epi-
topesonly havemoderate orweakbinding aﬃnities toHLA-A2
molecules. This shows that not only strongbindingHPV16-
derivedpeptides but alsoweakHLAbinders are presented to
T-cells for immune recognition.Our results contribute to a
better understandingof epitopepresentation inHPV-induced
cancers and thedetectedpeptideswill be used for future im-
munotherapy development. Furthermore, the described strat-
egy canbe applied for thedetectionof other low-abundant
epitopes, such asmutation-derivedneoepitopes,which are
usuallymissedwith untargeted LC-MS2 acquisition.
are highly polymorphic, and each type binds diﬀerent peptides
based on the respective anchor motifs.[3,4] In this study, we in-
vestigated HLA-A2-restricted peptides since HLA-A2 is the most
common HLA allele worldwide.[5]
Due to the expression of viral proteins, human papillomavirus
(HPV)-mediated cancers are among the tumors that can be
targeted by immunotherapies. High-risk types of HPV cause
anogenital and oropharyngeal cancer. The most important HPV-
induced malignancy is cervical cancer, which is the fourth most
common cancer in women worldwide.[6] The vast majority of
cervical cancer is caused by HPV16 and HPV18 (60 and 15%
of cases, respectively).[6,7] The likelihood to get infected with a
high-risk HPV type and consequently develop cancer was re-
duced after prophylactic vaccines became available for immu-
nization of adolescents in 2006.[8] However, these vaccines have
no therapeutic eﬀects in already infected individuals. It has been
shown that T-cell responses against HPV-derived epitopes ef-
fectively cleared HPV infections.[9] Thus, immunotherapeutic
strategies targeting the HPV oncoproteins E6 and E7, which
are expressed in all stages of HPV-mediated carcinogenesis, are
actively pursued to induce eﬀective clearance of HPV in in-
fected individuals.[10,11] One possible approach is direct identi-
ﬁcation of HPV-derived epitopes that are naturally presented
on the surface of HPV-transformed cells, and developing ther-
apeutic vaccinations based on these validated targets. To date,
several HLA-A2-restricted HPV16 target epitopes were identi-
ﬁed with indirect biological assays.[12] However, only one HLA-
A2-restricted HPV16 peptide, E711–19, was directly detected on
the surface of HPV16+ cell lines[13] and primary tumors.[14] This
is probably due to the fact that the amounts of HPV epitopes
presented on the cell surface are extremely low, because of
low viral protein expression and known HPV immune evasion
mechanisms.[15,16]
Also epitopes derived from other viral proteins andmany neoepi-
topes are presented at low abundance, and thus pose challenges
to direct identiﬁcation approaches. Therefore, the aim of the
present study was to develop a sample preparation strategy that
allowed high isolation yields of low-abundant target peptides
combined with a targeted LC-MS detection strategy with two
consecutive MS fragmentation stages (MS3), which would allow
considerably higher sensitivity necessary for low-abundant pep-
tide detection.[17]
2. Experimental Section
In Silico Predictions: In silico predictions for HLA-A*0201 bind-
ing were performed for HPV16 E6 and E7 proteins with 11 web-
accessible algorithms. The predictions were performed for 8–11-
mer peptides with NetMHC 4.0,[18] NetMHC 3.4,[19] NetMHCpan
3.0,[20] NetMHCpan 2.8,[20] NetMHCcons 1.1,[21] Consensus,[22]
PickPocket 1.1,[23] SMM,[24] SMMPMBEC,[25] BIMAS,[26] and
SYFPEITHI.[27] Results of all prediction algorithms were com-
bined. To ensure not to miss potential binders at this stage, after
starting with the recommended cut-oﬀs of the respective algo-
rithm, the prediction cut-oﬀs were lowered stepwise based on ac-
tual binding of tested peptides in the in vitro binding assays, until
no more binders could be detected.
Cell Lines, Media: Adherent HLA-A2+ HPV16+ CaSki cer-
vical cancer cells (ATCC CRL-1550) and suspension HPV16-
negative HLA-A2+ BSM cells (IHWG Cell Bank) were used in
this study. CaSki cells were cultivated in RPMI-1640 medium
supplemented with 10% heat-inactivated FCS and 1% peni-
cillin/streptomycin (all Sigma-Aldrich, Taufkirchen, Germany).
BSM cells were cultivated in RPMI-1640 supplemented with 15%
heat-inactivated FCS and 1 mm sodium pyruvate (PAA Labora-
tories, Co¨lbe, Germany). Cells were kept under standard con-
ditions in a humidiﬁed incubator at 37 °C and 5% CO2. They
were authenticated[28] and regularly checked for contaminations
bymultiplex PCR[29] by theDKFZGenomics and Proteomics core
facility.
Synthetic Peptides: All synthetic peptides used in this study
were produced with a purity of >95% at the DKFZ peptide pro-
duction unit. Peptides were dissolved in DMSO at 10 mg mL−1
and stored in small aliquots at −80 °C.
In Vitro Competition Based Binding Assays: In vitro competition-
based binding assays were performed as described in ref. 30. In
brief, BSM cells were treated with citric acid buﬀer to strip oﬀ
naturally presented peptides. Cells were incubated overnight at
4 °C with β2M, a constant concentration (150 nm) of ﬂuorescein-
labeled HLA-A2-binding reference peptide (FLPSDC(Fl)FPSV),
and six diﬀerent concentrations (0.78 –100 μm) of the respective
investigated non-labeled peptide, competing for HLA-binding.
Fluorescence was measured by ﬂow cytometry and data pro-
cessed with FlowJo 10 (TreeStar, Ashland, OR, USA). A lo-
gistic four-parametric non-linear regression calculation using
SigmaPlot 13 (Systat-Software, San Jose´, CA, USA) was con-
ducted to calculate binding aﬃnity (IC50). The IC50 value is
deﬁned as the test peptide concentration that inhibits bind-
ing of the ﬂuorescently labeled reference peptide by 50%.
Peptides were classiﬁed as strong (IC50 < 5 μm), intermedi-
ate (IC50 5–15 μm), weak (IC50 15–100 μm), or non-binders
(IC50 > 100 μm) according to ref. 30. The assay was performed
with at least three biological replicates for binders and two for
non-binders.
Immunoprecipitation of Peptide/HLA-A2 Complexes: 5 × 108
CaSki (for HPV peptide analysis) or BSM cells (for control pur-
poses) were collected by scraping or pelleting, respectively, and
lysed with a lysis buﬀer containing 1.2% CHAPS (AppliChem,
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Darmstadt, Germany) or 1% IGEPAL CA-630 (Sigma-Aldrich),
protease inhibitor cocktail (cOmplete-Mini, Roche, Mannheim,
Germany) and 1 mm PMSF (Roth, Karlsruhe, Germany) in PBS.
Cell lysates were centrifuged to remove cell debris (22 000 × g,
4 °C, 30 min). Peptide/HLA-A2 complexes were isolated via IP
from cleared cell lysates by mouse-anti-human-HLA-A2 (clone
BB7.2) antibody coupled to GammaBind Sepharose beads (GE
Healthcare, Uppsala, Sweden) for 4 h at 4 °C. IP samples were
washed seven times with 15 mL ice-cold PBS, transferred to
1.5 mL tubes and washed four times with 1.5 mL ice-cold
PBS.
Peptide Elution and Puriﬁcation from IP Samples by Ultra-
ﬁltration and Reverse Phase Materials: Peptides were eluted
from isolated peptide/HLA complexes (pHLA) with 0.3% TFA
(ProteoChem, Denver, CO, USA) in LC-MS-grade water (Bio-
solve, Valkenswaard, The Netherlands). Three ultraﬁltration de-
vices (Vivacon 500 2 kDa or 10 kDa cut-oﬀ, Sartorius Stedim,
Go¨ttingen, Germany; Amicon 3 kDa cut-oﬀ, Merck-Millipore,
Cork, Ireland) were used. Peptide RP puriﬁcation was performed
with 1 mL Sep-Pak tC18 cartridges (Sep-Pak; Waters, Milford,
MA, USA), with in-house assembled microcolumns in 200 μL
pipette tips as in ref. 31, ﬁlled with Zorbax SB-C18 5 μm (Agi-
lent Technologies, Santa Clara, CA, USA) or with OligoR3 50μm
(Applied Biosystems, Bedford, MA, USA) material. The resulting
protein fractions were subjected to in-solution reduction, alkyla-
tion, and digestion, and subsequently analyzed by LC-MS with
solid-phase extraction capillary liquid chromatography (speLC)
coupled to a Q-Exactive instrument. The exact experimental pro-
cedures of assessment of peptide puriﬁcation are given in Mate-
rials and Methods, Supporting Information.
Detergent Removal: To examine removal of the nonionic deter-
gent IGEPAL CA-630 from IP samples, ion exchange was per-
formed with microcolumns ﬁlled with strong cation exchange or
strong anion exchange materials. Target peptide recoveries were
assessed by targeted LC-MS2. The eﬃciency of detergent removal
by the material giving the highest target peptide yield was ana-
lyzed by MALDI-TOF MS1. Experimental details are provided in
Materials and Methods, Supporting Information.
Detection of HLA-A2-Presented Peptides by Targeted LC-
MS3 Mass Spectrometry: The optimized sample prepara-
tion steps were applied to IP samples of the HLA-A2+
HPV16+ cervical cancer cell line CaSki. All 17 HPV16-
derived peptides that were determined to be HLA-A2
binders in the cellular binding assays and two endogenous
control HLA-A2 binders (derived from housekeeping pro-
teins) were used for generation of LC-MS3 methods. These
19 peptides were monitored in the CaSki IP samples. A min-
imum of three biological replicates was measured for each
experiment. Reference spectra of synthetic peptides were man-
ually compared by three independent researchers (R.B., N.M.,
M.S.) to the spectra of IP samples to conﬁrm the presence of
target peptides. The criteria for positive identiﬁcation were as
follows: First, retention times for the peptide detected in the IP
sample and its corresponding synthetic peptide had to coincide.
Second, the extracted ion chromatograms for all transitions
(an m/z pair of a precursor and a fragment ion) had to be
measured concurrently and in correct hierarchy of abundance
in IP samples and for the synthetic reference peptides. Finally,
MS3 spectra were monitored for a minimum of three transitions
and were required to match between the synthetic peptide and
the peptide identiﬁed in the IP sample. Only peptides that were
assessed to fulﬁl all criteria by all three independent researchers
were considered to be detected. Detailed MS measuring parame-
ters and data processing speciﬁcations are provided in Materials
and Methods and Table S1, Supporting Information. Data have
been deposited in PeptideAtlas, with the Identiﬁer PASS01152.
As PeptideAtlas data are handled by ProteomeCentral, and thus
exchanged with PRIDE, our data will also be available to the
newly established SysteMHC Atlas project.[32]
Immunogenicity Assessment by Interferon-γ ELISpot: Periph-
eral blood mononuclear cells (PBMCs) were isolated from buﬀy
coats from anonymous healthy blood donors (obtained from
DRK blood bank Mannheim), under the local IRB approval
S-394/2011. We only used buﬀy coats from female donors
>40 years of age, to increase the likelihood of a previous HPV16
encounter. PBMCs were isolated by standard density centrifuga-
tion with Ficoll-Paque Plus (GE Healthcare, Uppsala, Sweden)
in Leucosep tubes (Greiner Bio-One, Frickenhausen, Germany).
They were further tested for HLA-A2 expression by staining with
a FITC-coupled anti-human HLA-A2 antibody (clone BB7.2) and
subsequent analysis by ﬂow cytometry.
1–2 × 106 HLA-A2+ PBMCs were seeded in RPMI-1640, sup-
plemented with 10% human serum, 1% penicillin/streptomycin,
2 mm L-Glutamine, 12 mmHEPES, 0.05 mm 2-mercaptoethanol
(all Sigma-Aldrich), and 10 ng mL−1 IL-7 (R&D Systems, Min-
neapolis, MN, USA) in the presence of HPV16-derived peptides
with a ﬁnal concentration of 10 μg mL−1. A HLA-A2-restricted
HIV1 peptide (LTFGWCFKL-HIV/Nef137-145) was used as neg-
ative control, 1 μg mL−1 of the CEF peptide pool (PANATecs,
Heilbronn, Germany) as positive control, and 1 μL mL−1 DMSO
(peptide diluent) as background control. On day 3 and 7, cells
were fed with 20 U mL−1 IL-2 (PeproTech, Rocky Hill, NJ,
USA). Cells were harvested on day 12, restimulated with the re-
spective peptide or control and seeded in triplicate wells at a
density of 1–2.5× 105 onMultiscreen-HAELISpot plates (Merck-
Millipore, Darmstadt, Germany) coated with 2 μg mL−1 of anti-
human interferon (IFN)-γ antibody (clone 1-D1K). After 24 h,
0.5 mg mL−1 biotinylated anti-human IFN-γ antibody (clone
7 B6-1) was used to develop the ELISpot according to the man-
ufacturer’s instructions (Mabtech AB, Nacka Strand, Sweden).
The number of spots was analyzed with a CTL ELISpot reader.
The number of spot-forming units (SFU) per 1 × 106 cells was
determined and expressed relative to the background control
(stimulation index, SI). A peptide-speciﬁc T-cell response was
considered positive when SI > 2 and SFU > 200 spots per
1 × 106 cells.
3. Results
The general strategy used in our study is shown in Figure 1. Bind-
ing of HPV16-derived peptides to HLA-A2 was predicted in sil-
ico. Predicted binders were tested for their true binding aﬃnity
to HLA-A2 molecules in competition-based cellular binding as-
says. Veriﬁed binders were used to design targeted LC-MS3 meth-
ods. Subsequently, pHLA were isolated from HPV16+ cells via
IP, peptides were puriﬁed and monitored by LC-MS3 analysis.
Detected peptides were assessed for immunogenicity.
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Figure 1. Workﬂow for direct identiﬁcation of epitopes presented on the cell surface. HPV16 E6/E7-derived peptides were predicted in silico for their
binding aﬃnities to HLA-A2. Predicted binders were tested for their actual binding aﬃnity in in vitro assays. Only conﬁrmed binders were monitored by
MS analysis after their isolation from HPV-transformed cells.
Figure 2. Experimentally determined and predicted binding aﬃnities for HLA-A2-restricted HPV16 E6/E7-derived peptides. In silico predictions were
conducted with 11 web-based algorithms. For clarity, only results from NetMHC 4.0 are displayed. Experimental binding aﬃnities were determined with
in vitro competition-based binding assays. The order of peptides is from strongest (top) to weakest (bottom) binding aﬃnity as determined in the in
vitro assays. Strong binders: experimental IC50 below 5 μm; intermediate binders: experimental IC50 5–15 μm (marked with light gray); weak binders:
experimental IC50 > 15–100 μm (marked with dark gray). Results are plotted as mean ± SD from at least three experimental replicates.
3.1. HLA-A2 Ligand Predictions and Cellular Binding Assays
In silico predictionswith adapted cut-oﬀs suggested 121 potential
HLA-A2 binders derived from HPV16 E6 and E7 proteins (data
not shown). Cysteine-containing peptides were excluded, as cys-
teines are prone to intra- and intermolecular disulﬁde bond for-
mation and therefore may complicate targeted MS analysis. The
binding aﬃnity of 58 non-cysteine-containing peptides was as-
sessed in competition-based cellular binding assays. We identi-
ﬁed 17 binding peptides, of which 9 were never reported before
(Figure 2). Seven peptides were strong, two peptides were inter-
mediate, and eight peptides were weak binders. As also shown
in Figure 2, predicted and experimental binding aﬃnities only
partially overlap.
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3.2. Optimization of Sample Preparation
pHLA were isolated from HPV16+ CaSki cells by HLA-A2-
speciﬁc IP. As low amounts of target peptides were expected
(due to known low expression levels of the viral source pro-
teins), we adapted the IP isolation and epitope extraction to
minimize puriﬁcation steps and peptide losses. In most cur-
rent epitope isolation workﬂows, peptides are dissociated from
the HLA complex by acidiﬁcation and further separated from
protein contaminants by ultraﬁltration. As high peptide losses
can be associated with ultraﬁltration, we compared several ul-
traﬁltration tubes and RP materials for most eﬃcient peptide
extraction. Our data show that the recovery of target HPV16
E6/E7-derived peptideswas better with RPmaterials thanwith ul-
traﬁltration (Figure S1, Supporting Information). Next, we tested
three RP materials for eﬃciency of separation of larger proteins
from target peptides by diﬀerential elution. Sample processing
on Zorbaxmicrocolumns resulted in least contaminating protein
amounts and best target peptide recoveries (Figure S2, Support-
ing Information), and was therefore chosen as our standard epi-
tope extraction strategy.
Since the high detergent content in the sample can interfere
with LC-MS analysis, it needs to be removed either directly af-
ter IP by extensive washing or during peptide extraction from IP
samples. To examine the possibility of removing the nonionic de-
tergent IGEPAL CA-630 during peptide extraction, we measured
peptide recovery from various ion exchangematerials. The strong
cation exchange material Poros 20HS showed highest peptide
yields (Figure S3, Supporting Information), and was thus further
tested for detergent removal eﬃciency. Even though we could
demonstrate removal of excess detergent (Figure S4, Supporting
Information), the procedure resulted in marked peptide losses.
Thus, for detergent removal, extensive washing of the IP sam-
ple directly after IP is preferable over additional sample handling
steps, and was incorporated in our sample preparation workﬂow.
3.3. Identiﬁcation of HLA-A2-Presented HPV16-Derived Peptides
We next employed the optimized IP and epitope extrac-
tion strategy—ensuring minimal protein and detergent
contaminations—to IP samples of HLA-A2+ HPV16+ CaSki
cells. All peptides that were experimentally identiﬁed as HLA-
A2 binders (Figure 2) were used for manual optimization of
LC-MS3 methods to assess their presence on HPV16-positive
cancer cells. The identity of target peptides in IP samples was
conﬁrmed with several criteria, as detailed in the Experimental
section and in the Methods section, Supporting Information.
It should be noted that most of the target peptides contained
methionine (Met). Detection challenges for these peptides are
shown in Figure S5, Supporting Information. Met-containing
peptides were only detected in the oxidized state (MetOx) in
the IP samples. Therefore, the MS3 spectra of detected MetOx
peptides had shifts of 8 or 16 m/z (for doubly or singly charged
ions, respectively) for all precursor ions and, depending on the
sequence, also the majority of fragment ions.
A peptide was considered to be detected when the identity cri-
teria were fulﬁlled for at least three of the monitored transitions
Table 1. LC-MS3 detection results of HLA-A2-restricted HPV16 E6/E7-
derived peptides from the surface of CaSki cells.
Peptide Sequence MS analysisa)
E711–19 YMLDLQPET Detected
E711–20 YMLDLQPETT LOD
E711–21 YMLDLQPETTD LOD
E77–15 TLHEYMLDL Detected
E777–87 RTLEDLLMGTL Detected
E782–90 LLMGTLGIV Detected
E712–20 MLDLQPETT —
E711–18 YMLDLQPE —
E780–90 EDLLMGTLGIV Detected
E77–17 TLHEYMLDLQP —
E776–86 IRTLEDLLMGT —
E625–33 ELQTTIHDI —
E710–19 EYMLDLQPET —
E712–19 MLDLQPET LOD
E778–86 TLEDLLMGT Detected
E777–86 RTLEDLLMGT Detected
E781–90 DLLMGTLGIV Detected
a)Detected: at least three monitored transitions gave MS3 spectrum ﬁngerprints
which matched those of the synthetic peptides. LOD, limit of detection: peptide de-
tected with only the two most intense transitions. All detected or LOD peptides had
matching retention times and extracted ion chromatogram patterns for all monitored
transitions between the IP sample and the synthetic peptide, and were detected in
a minimum of two biological replicates. —, not detected; Grey shading indicates
HLA-A2 binding aﬃnity, as in Figure 2.
in at least two biological replicates. A peptide was considered
present at the limit of detection (LOD) when only two of themon-
itored transitions were detected in the IP sample—but again in
at least two biological replicates. The only exception is the MetOx
form of peptide E711–19, where the intensity of the third possi-
ble transition was so low that we excluded it from the analysis,
thus onlymonitored two transitions, and still designated the pep-
tide “detected” if these two transitions were seen. With this ap-
proach, we detected 11 out of the 17 monitored HPV16 peptides,
three of them at LOD (Table 1). Interestingly, all detected pep-
tides were derived from protein E7, but there was only one E6-
derived peptide among the monitored peptides from the start.
Detection of a strong HLA-A2-binding peptide (E77–15), an inter-
mediate binder (E780–90), and a peptide with low binding aﬃnity
to HLA-A2 (E777–86) are shown in Figure 3. Spectra for all other
detected peptides are shown in Figure S6, Supporting Informa-
tion, and details about monitored and detected transitions are
given in Table S1, Supporting Information.
3.4. Immunogenicity Assessment of Detected Peptides
Conﬁrming T-cell reactivity against identiﬁed peptides is neces-
sary to designate HLA-presented peptides true T-cell epitopes.
To this end, we performed a screen for memory responses by
IFN-γ ELISpot against all 11 detected HPV16-derived peptides
with T-cells from HLA-A2+ healthy donors, which were selected
for high likelihood of previous HPV encounter. Out of 14 tested
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Figure 3. Extracted ion chromatograms for measured transitions and MS3 spectra for selected peptides in an IP sample and from respective synthetic
peptides. A, B) Strong binder E77–15 TLHEYMLDL; C, D) intermediate binder E780–90 EDLLMGTLGIV; E, F) weak binder E777–86 RTLEDLLMGT. CaSki IP
samples were processed with Zorbax microcolumns and analyzed with LC-MS3. All these Met-containing peptides were detected in their oxidized form.
For easier comparison, the results for the IP sample and the synthetic peptide are displayed on the same axis. Representative results of one out of at
least three biological replicates are shown. B, D, F) m/z values are indicated in black, fragment annotations in red. T, threonine.
donors, 8 showed reactivity against any of the tested peptides, in-
dicating prior exposure to HPV16. Interestingly, the highest and
most frequent responses were observed against E711–19, which
is the only peptide already detected to be presented on the cell
surface of HPV16+ cells in a previous study.[13] The overlapping
peptide E712–19 also showed responses in four donors, albeit
slightly weaker than the ones against E711–19. Ninemore peptides
elicited T-cell responses in one to two donors (Figure 4), which
means that all of the peptides detected by our targeted LS-MS3
approach could be demonstrated to be immunogenic.
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Figure 4. Immunogenicity assessment of detected peptides by IFN-γ
ELISpot. PBMC reactivity of 14 HLA-A2+ healthy donors was evaluated by
in vitro stimulation for 12 days with selected HPV16-derived peptides. A)
Representative ELISpot results of one donor showing a positive and a neg-
ative response against two HPV16-derived peptides. CEF, positive control;
HIV, negative control. B) Reactivities of all HPV16-reactive donors (n= 8),
shown as stimulation index (number of spot-forming units relative to re-
spective background control). Mean responses (±SD) across donors are
shown for each peptide, cut-oﬀ for positive responses: SI  2 (dashed
line). White numbers in columns: number of reactive donors per peptide.
4. Discussion
To date, there are no therapeutic options for high-risk HPV in-
fections except surgical removal of the aﬀected tissue. HPV-
speciﬁc immunotherapies would represent an attractive alterna-
tive. However, HPV-derived epitopes are only presented at low
abundance at the surface of infected and transformed cells, as
one major HPV immune evasion mechanism is to keep the
expression levels of its proteins low throughout the viral life
cycle.[15] Moreover, HPV proteins inﬂuence the antigen process-
ing machinery and can thereby reduce cell surface presentation
of certain HPV epitopes.[33] In consequence, identiﬁcation of
HPV epitopes that represent valid targets for immunotherapies
has so far remained a challenge.
Therefore, we here tailored a highly sensitive targeted LC-MS3
approach for direct identiﬁcation of naturally presentedHPV epi-
topes. Using this strategy, we monitored 17 HLA-A2 binders and
provided evidence for the cell surface presentation of 11 HPV16
E7-derived peptides, 10 of which were detected byMS for the ﬁrst
time.
LC-MS-based detection of HLA-binding peptides is usu-
ally performed after IP of pHLA and subsequent peptide
extraction.[34] Most studies to date used untargeted unbiased LC-
MS2 detection, which detects large numbers of epitopes pre-
sented at higher abundance. Untargeted detection was used
for identiﬁcation of HLA binding motives,[35] viral epitopes,[36]
and tumor mutation-derived epitopes (neoepitopes) from can-
cer cell lines[37,38] or primary human tumor material.[39,40] How-
ever, this common workﬂow fails to identify low-abundant
peptides that might still be important for immunotherapy devel-
opment. Recently, data-independent acquisition mass spectrom-
etry has been applied for HLA-I peptide discovery,[41,42] which,
however, needs compatible instrumentation. Another possibility
that was recently utilized for sensitive detection as well as quan-
tiﬁcation of HLA-I peptides is targeted data acquisition.[38,43–47]
Also in the present study, we used a targeted LC-MS3 approach,
which is more sensitive for detection of HLA-presented peptides
than untargeted methods due to pre-deﬁned and pre-programed
analytes, resulting in longer acquisition times per analyte for in-
creased sensitivity. Moreover, the optimization of the collision en-
ergy of individual transitions performed on the synthetic counter-
parts of the peptides to be analyzed has shown an about twofold
sensitivity gain compared with the signals obtained from more
generic collision energies computed from the mass of the tar-
geted precursor, which makes this optimization process partic-
ularly suited for the detection of low-abundant HLA-presented
peptides (reviewed in ref. 48), such as the HPV peptides investi-
gated in this study. Furthermore, MS3 scanning approaches are
less prone to interference of co-eluting species than MS1 or MS2
methods.[49,50] The main downside of targeted MS3 approaches is
a limited number of analytes that can be measured in one LC-
MS3 analysis. Furthermore, only a small number of dedicated
bioinformatic tools is available for MS3 data. Therefore, a reduc-
tion of the number of target peptides is necessary. This can be
achieved with in silico predictions and in vitro scanning of can-
didate epitopes for their experimental binding aﬃnities. How-
ever, in vitro binding assays are laborious and are therefore often
omitted. By employing predictions as well as binding assays, and
analyzing only non-cysteine-containing peptides, we reduced the
number of possible HPV16 E6/E7-derived HLA-A2-binding pep-
tides to 17 actual binders, of which 9 had never been described
before (Figure 2). The binding aﬃnity results for already reported
peptides were in accordance with our results, although they were
tested with diﬀerent in vitro assays.[12,13]
We adapted the isolation of pHLA from typical on-column
to in-solution IP to reduce volumes and contact surfaces for
minimal losses of low-abundant target peptides, as it has been
shown that the IP step introduces most losses during sample
pretreatment.[46] Moreover, our approach does not require peri-
staltic pumps or special LC equipment and can therefore be
performed in any laboratory. For low-abundant peptides, maxi-
mal recovery and high preparative yields are particularly relevant
throughout the whole peptide puriﬁcation pipeline. Thus, we ex-
changed the commonly used ultraﬁltration with RP material ex-
traction. We compared three RP materials; OligoR3, Zorbax and
Sep-Pak. The best target peptide recoveries and the most eﬀec-
tive removal of protein contaminants were achieved with Zorbax
microcolumns. Thus, this material was chosen for our standard
HLA-I peptide puriﬁcation workﬂow. The high performance of
the Zorbaxmaterial within this applicationmay be explainedwith
its pore size. According to the product speciﬁcations, the pore
sizes were 80 A˚, 130 A˚, and 300–3000 A˚ for Zorbax, Sep-Pak, and
OligoR3, respectively. The bigger the pore size, themore proteins
can bind to the RP material. This underlines that the pore size
of RP material is an important parameter to be considered for
separation of proteins and peptides[51,52] and can be exploited for
HLA-I peptide isolation.
Cell lysis for pHLA IP is usually performed with lysis buﬀers
containing non-denaturing detergents. The most common de-
tergents are CHAPS and IGEPAL CA-630. Detergents have to
be removed before downstream LC-MS analysis as they signiﬁ-
cantly inﬂuence peptide separation on the LC column[53,54] or in-
terfere with ionization of analytes.[55,56] Therefore, thorough and
repeated washing of IP samples is necessary. If for reasons inher-
ent to experimental setups detergent removal from the IP sample
cannot be performed, we demonstrated that non-ionic detergents
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(such as IGEPAL CA-630) could be removed by ion exchange
(IXC) during the subsequent peptide extraction. This is not pos-
sible for zwitterionic detergents such as CHAPS. The choice of
IXC material depends on the sequence of target peptides, which
is tightly connected to theHLAbindingmotives and is distinct for
each HLA allele.[3,4] For example, the anchor residues on position
9 (P9) in HLA-A11-restricted peptides are typically R or K, which
results in peptides with at least one basic amino acid, whereas
the preferential amino acids for HLA-A2-binding peptides on P2
and P9 are small or aliphatic hydrophobic residues (L, I, V, M,
A, T, or Q).[3] As another example, Met is often found on P1 and
P3 in HLA-A2-binding peptides. This results in many hydropho-
bic, Met-containing peptides, often without any basic amino acid,
which was also reﬂected in the characteristics of the target pep-
tides in this study. As the SCX Poros 20HS material, which gave
the best results for our HPV16-derived HLA-A2-restricted pep-
tides, is known to work best with basic peptides, it is reasonable
to assume that it will also be suited for other HLA peptides with
more basic chemical characteristics.
Our optimized peptide isolation strategy and highly sensitive
targeted LC-MS3 analysis resulted in identiﬁcation of 11HLA-A2-
restricted HPV16 E7-derived peptides on CaSki cells (Table 1) out
of 17 monitored. The reason for this rather high ratio may be our
strategy of only looking for peptides whose HLA-A2 binding ca-
pacity had been experimentally conﬁrmed, which is in contrast
to most other studies, which search for predicted HLA-binding
peptides. Only one identiﬁed peptide, E711–19, was detected byMS
before.[13,14] The major diﬀerence of our strategy compared to the
approach described in ref. 13,14 is a faster and more sensitive
MS instrumentation. This allowed for online LC-MS3 analysis of
IP samples and measurement of more peptides in one analysis,
whereas the authors of the earlier studiesmeasured only one pep-
tide at a time via static nanospray.
Interestingly, many detected peptides were predicted as HLA-
A2 non-binders with the 500 nm cut-oﬀ recommended by the pre-
diction algorithms, indicating that this cut-oﬀ may be too strict.
This phenomenon was also observed for HLA-B*3503 binding
peptides identiﬁed by MS, which had been predicted as non-
binders.[39] Furthermore, we detected peptides from the whole
range of experimental binding aﬃnities, half of them interme-
diate or low-aﬃnity binders. This shows that it is important to
not only focus on the best (predicted) binders, but to also mon-
itor peptides with moderate or weak binding aﬃnities to the
respective HLA molecule, as these also may be presented to
T-cells for immune recognition. Indeed, we found T-cell reac-
tivity against all of the 11 MS-detected peptides (Figure 4), sug-
gesting that our detection approach has high predictive value for
immunogenicity. Obviously, this will have to be tested in larger
data sets, but stresses the importance of correlating MS-veriﬁed
HLA-presented peptides and immunogenicity data, an issue that
is currently not addressed by the existing literature (reviewed in
ref. 57).
In conclusion, we here describe a highly sensitive targeted LC-
MS3 methodology for detection of low-abundant epitopes on the
surface of cancer cells. We are currently applying this method-
ology to HPV peptides presented by other HLA molecules, and
are working on methods allowing monitoring of Cys-containing
peptides. These results will contribute to a better understanding
of HPV-mediated changes in epitope presentation, and provide
a solid basis of targets for HPV immunotherapy development.
As the sequences of possible mutation-derived tumor neoepi-
topes are known from tumor genome sequencing projects, our
methodology can also be used for ascertaining the presentation
of neoepitopes on the tumor cells surface. This in turn will facili-
tate the development of immunotherapies for other tumor types.
On a broader scale, knowledge about truly presented epitopes will
improve epitope prediction servers, which will hopefully make
target epitope deﬁnition an easier task in the future.
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